Polo-like kinase 1 (PLK1), a key regulator of mitosis, is often overexpressed in childhood cancers and is associated with poor prognosis. Previous reports have shown that inhibition of PLK1 might serve as a promising anticancer treatment for osteosarcoma. In this study, we tested the second-generation PLK1 inhibitors BI 6727 and GSK461364 in HOS and MG-63 cell lines, both as a single agent and in combination with methotrexate, cisplatin, vinblastine, doxorubicin, or ionizing radiation. Both PLK1 inhibitors worked equally in terms of cell growth arrest, apoptosis induction, and radiosensitization. Combining BI 6727 or GSK461364 with conventional treatments, however, showed trivial synergistic antitumor effects in vitro. Our results reinforce the potential use of PLK1 inhibitors for a pharmacologic intervention in osteosarcoma, although their applicability in polychemotherapeutic regimens deserves further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000000157 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.
Zhejiang Da Xue Xue Bao Yi Xue Ban
October 2023
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Article Synopsis
- This study explores the impact of PLK1 inhibitors on non-small cell lung carcinoma (NSCLC) cells that have developed resistance to osimertinib, an existing targeted therapy.
- Experiments demonstrated that combining PLK1 inhibitors like GSK 461364 and BI 2536 with osimertinib significantly enhances anti-tumor effects compared to using osimertinib alone.
- Results indicate that the activation of specific signaling pathways in osimertinib-resistant cells correlates with reduced patient survival, suggesting that targeting these pathways may improve treatment outcomes.
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
Endocr Relat Cancer
August 2019
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Polo-like kinases (PLKs) are pivotal regulators of cell proliferation and cell survival; therefore, PLKs may be potential targets in the treatment of malignancy. The therapeutic effects of volasertib, a PLKs inhibitor for papillary and follicular thyroid cancer (known as well-differentiated thyroid cancer (WDTC)), were evaluated in this study. Volasertib inhibited cell proliferation in two papillary and two follicular thyroid cancer cell lines in a dose-dependent manner.
View Article and Find Full Text PDFPLK1 Inhibition Radiosensitizes Breast Cancer Cells, but Shows Low Efficacy as Monotherapy or in Combination with other Cytotoxic Drugs.
Anticancer Agents Med Chem
June 2019
Department of Pediatrics, Ribeirao Preto School of Medicine, University of Sao Paulo, Sao Paulo, Brazil.
Article Synopsis
- The study explored the in vitro effects of two second-generation PLK1 inhibitors, BI 6727 and GSK461364, on breast cancer cell lines, examining their potential to inhibit cell growth alone or in combination with other treatments like radiation.
- Results showed that while the inhibitors had minimal impact on cell survival, they significantly reduced the ability of cancer cells to form colonies and improved their sensitivity to radiation, especially when combined with other chemotherapy drugs.
- The findings suggest that despite overexpression of PLK1 in certain breast cancer types, effective inhibition is only evident through specific assays, indicating that differences in genetic and biological factors within breast cancer may affect treatment responses and future strategies for personalized therapy.
Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
Anticancer Agents Med Chem
October 2017
Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto. Brazil.
Background: Medulloblastoma (MB) is one of most frequent malignant tumors that affect children. Despite the relatively good survival rate, long time sequels still represent a challenge for MB. Therefore, in an attempt to reduce treatment aftereffects, new therapeutic targets are constantly being explored.
View Article and Find Full Text PDFEffect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.
Cancer Sci
December 2016
Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Polo-like kinase (PLK) is a cell-cycle regulator that is overexpressed in several cancer cell types. Polo-like kinase is considered a novel target for cancer therapies, and several PLK inhibitors (PLKis), including BI 2536, BI 6727, and GSK461364, have been developed. In this study, we established five BI 2536-resistant cell lines from human colorectal cancer HCT 116 cells, to explore the resistance mechanism and identify predictable biomarkers of PLKis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!